LIDDS AB (publ) (LIDDS.ST)
Key Executives
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
| Mats Wiking | CEO, CFO & Head of IR | -- | -- | 1969 |
| Ms. Monica Wallter | Senior Advisor | 1.87M | -- | 1956 |
| Ms. Kia Bengtsson | Head of Clinical Development | -- | -- | 1969 |
| Dr. Roger Belusa | Chief Medical Officer | -- | -- | -- |
LIDDS AB (publ)
- Sector:
- Healthcare
- Industry: Biotechnology
- Full Time Employees:
- 1
Description
LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden.
Corporate Governance
Upcoming Events
May 29, 2025 at 10:59 AM UTC
LIDDS AB (publ) Earnings Date
Recent Events
Recent Events Information Not Available